RaQualia Pharma, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3967150008
JPY
1,302.00
1 (0.08%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor Management Efficiency with a low ROE of 4.41%

  • The company has been able to generate a Return on Equity (avg) of 4.41% signifying low profitability per unit of shareholders funds
2

Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 4.41%

 
3

With a fall in Operating Profit of -1866.07%, the company declared Very Negative results in Jun 25

4

Risky - Negative Operating Profits

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

JPY 12,579 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.10

stock-summary
Return on Equity

-9.32%

stock-summary
Price to Book

2.00

Revenue and Profits:
Net Sales:
571 Million
(Quarterly Results - Jun 2025)
Net Profit:
-350 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
124.1%
0%
124.1%
6 Months
100.93%
0%
100.93%
1 Year
205.63%
0%
205.63%
2 Years
52.1%
0%
52.1%
3 Years
-6.13%
0%
-6.13%
4 Years
43.87%
0%
43.87%
5 Years
26.29%
0%
26.29%

RaQualia Pharma, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
18.29%
EBIT Growth (5y)
2.10%
EBIT to Interest (avg)
62.14
Debt to EBITDA (avg)
22.67
Net Debt to Equity (avg)
0.06
Sales to Capital Employed (avg)
0.34
Tax Ratio
65.96%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.16%
ROE (avg)
4.41%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.00
EV to EBIT
-102.34
EV to EBITDA
69.76
EV to Capital Employed
2.88
EV to Sales
4.92
PEG Ratio
NA
Dividend Yield
0.00%
ROCE (Latest)
-2.82%
ROE (Latest)
-8.11%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -25.17% vs 18.47% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -42.19% vs -241.35% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "570.60",
          "val2": "762.50",
          "chgp": "-25.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-163.90",
          "val2": "-152.30",
          "chgp": "-7.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "16.20",
          "val2": "14.40",
          "chgp": "12.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "10.70",
          "val2": "-25.40",
          "chgp": "142.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-349.50",
          "val2": "-245.80",
          "chgp": "-42.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-496.50%",
          "val2": "-260.60%",
          "chgp": "-23.59%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 63.45% vs -34.85% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -52.92% vs -144.75% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3,107.60",
          "val2": "1,901.20",
          "chgp": "63.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "188.30",
          "val2": "-161.80",
          "chgp": "216.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "184.10",
          "val2": "6.70",
          "chgp": "2,647.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-23.50",
          "val2": "-21.70",
          "chgp": "-8.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-495.00",
          "val2": "-323.70",
          "chgp": "-52.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-68.70%",
          "val2": "-177.40%",
          "chgp": "10.87%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
570.60
762.50
-25.17%
Operating Profit (PBDIT) excl Other Income
-163.90
-152.30
-7.62%
Interest
16.20
14.40
12.50%
Exceptional Items
10.70
-25.40
142.13%
Consolidate Net Profit
-349.50
-245.80
-42.19%
Operating Profit Margin (Excl OI)
-496.50%
-260.60%
-23.59%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is -25.17% vs 18.47% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -42.19% vs -241.35% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
3,107.60
1,901.20
63.45%
Operating Profit (PBDIT) excl Other Income
188.30
-161.80
216.38%
Interest
184.10
6.70
2,647.76%
Exceptional Items
-23.50
-21.70
-8.29%
Consolidate Net Profit
-495.00
-323.70
-52.92%
Operating Profit Margin (Excl OI)
-68.70%
-177.40%
10.87%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 63.45% vs -34.85% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -52.92% vs -144.75% in Dec 2023

stock-summaryCompany CV
About RaQualia Pharma, Inc. stock-summary
stock-summary
RaQualia Pharma, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available